Global Varicella Vaccine Market Growth 2023-2029

Global Varicella Vaccine Market Growth 2023-2029

Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin

LPI (LP Information)' newest research report, the “Varicella Vaccine Industry Forecast” looks at past sales and reviews total world Varicella Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Varicella Vaccine sales for 2023 through 2029. With Varicella Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Varicella Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Varicella Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Varicella Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Varicella Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Varicella Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Varicella Vaccine.

The global Varicella Vaccine market size is projected to grow from US$ 4083.2 million in 2022 to US$ 7039.5 million in 2029; it is expected to grow at a CAGR of 7039.5 from 2023 to 2029.

Global Varicella Vaccine key players include Merck, Shanghai Institute, Changsheng, Keygen, GSK, etc.

Asia is the largest market, with a share over 35%, followed by US and Europe, both have a share over 55%.

In terms of product, Freeze-Dried Powder is the largest segment, with a share over 50%. And in terms of application, the largest application is Kids Injection, followed by Adults Injection, etc.

This report presents a comprehensive overview, market shares, and growth opportunities of Varicella Vaccine market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Injection

Freeze-Dried Powder

Segmentation by application

Kids Injection

Adults Injection

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Merck

GSK

Shanghai Institute

BCHT

Changsheng

Keygen

Green Cross

Biken

Key Questions Addressed in this Report

What is the 10-year outlook for the global Varicella Vaccine market?

What factors are driving Varicella Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Varicella Vaccine market opportunities vary by end market size?

How does Varicella Vaccine break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.